List of Vijoice drug patents
Vijoice is owned by Novartis.
Vijoice contains Alpelisib.
Vijoice has a total of 2 drug patents out of which 0 drug patents have expired.
Vijoice was authorised for market use on 05 April, 2022.
Vijoice is available in tablet;oral dosage forms.
Drug patent challenges can be filed against Vijoice from 2023-05-25.
The generics of Vijoice are possible to be released after 28 September, 2030.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8476268 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2029
(6 years from now) | |
| US8227462 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 24, 2024 |
| Orphan Drug Exclusivity (ODE) | Apr 5, 2029 |
Drugs and Companies using ALPELISIB ingredient
NCE-1 date: 2023-05-25
Market Authorisation Date: 05 April, 2022
Treatment: NA
Dosage: TABLET;ORAL
VIJOICE family patents
5
United States
3
European Union
2
Argentina
2
Cyprus
2
Hungary
1
Uruguay
1
Panama
1
Spain
1
Hong Kong
1
Dominican Republic
1
Malaysia
1
Denmark
1
RS
1
Poland
1
China
1
Brazil
1
Canada
1
Ukraine
1
Morocco
1
EA
1
Norway
1
Japan
1
ME
1
Nicaragua
1
New Zealand
1
Croatia
1
Korea, Republic of
1
San Marino
1
Honduras
1
Peru
1
Israel
1
Chile
1
Portugal
1
Taiwan
1
El Salvador
1
Georgia
1
Jordan
1
Mexico
1
Australia
1
Cuba
1
Costa Rica
1
Ecuador
1
Netherlands
1
South Africa
1
Colombia
1
Lithuania
1
Tunisia
1
Slovenia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic